Article
Serum BPSA may distinguish BPH from prostate Ca
San Francisco--Serum BPSA, an antigen enriched in the nodular transition zone tissue in BPH, appears to be a better predictor of clinically significant prostate enlargement than PSA or free PSA. This finding and complementary data, by researchers from the Scott Department of Urology, Baylor College of Medicine, Houston, lay the groundwork for further study that will determine the antigen's potential to distinguish between BPH and prostate cancer.
Related Videos
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Adoption of New Treatment Modalities to Treat BPH
Safety data on Black patients from ARANOTE
Current Unmet Needs in ccRCC Diagnosis
Decision-Making in Small Renal Masses
Related Content
